NCT06616623 - Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC V8

Interventions

BIOLOGICAL

Atezolizumab

Given IV

PROCEDURE

Biospecimen Collection

Undergo tissue and blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Vismodegib

Given PO

Trial Locations (1)

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus